8.25

1.20% -0.10

Kyverna Therapeutics Inc (KYTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$8.35

Offen:

$8.26

24-Stunden-Volumen:

499.07K

Relative Volume:

0.50

Marktkapitalisierung:

$510.21M

Einnahmen:

Nettoeinkommen (Verlust:

$-156.40M

KGV:

-2.5153

EPS:

-3.2799

Netto-Cashflow:

$-151.53M

1W Leistung:

-1.43%

1M Leistung:

+6.04%

6M Leistung:

-6.99%

1J Leistung:

+127.27%

1-Tages-Spanne:

$8.20

$8.38

1-Wochen-Bereich:

$7.6001

$8.78

52-Wochen-Spanne:

$3.60

$13.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Firmenname

Kyverna Therapeutics Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(510) 626-8331

Adresse

5980 HORTON STREET, EMERYVILLE

Mitarbeiter

129

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

KYTX's Discussions on Twitter

Compare KYTX vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KYTX Kyverna Therapeutics Inc	8.25	502.79M	0	-156.40M	-151.53M	-3.2799
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-20	Eingeleitet	William Blair	Outperform
2025-05-27	Hochstufung	H.C. Wainwright	Neutral → Buy
2024-10-10	Eingeleitet	UBS	Buy
2024-10-09	Eingeleitet	Rodman & Renshaw	Buy
2024-07-03	Eingeleitet	H.C. Wainwright	Neutral
2024-03-04	Eingeleitet	JP Morgan	Overweight
2024-03-04	Eingeleitet	Leerink Partners	Outperform
2024-03-04	Eingeleitet	Morgan Stanley	Overweight
2024-03-04	Eingeleitet	Wells Fargo	Overweight

Alle ansehen

Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten

Aug 20, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat

Aug 20, 2026

Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®

Aug 20, 2026

Aug 18, 2026

Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn

Aug 18, 2026

KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits

Aug 18, 2026

Aug 17, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat

Aug 17, 2026

AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 17, 2026

Aug 15, 2026

Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 15, 2026

Aug 14, 2026

KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet

Aug 14, 2026

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat

Aug 14, 2026

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan

Aug 14, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Aug 13, 2026

KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn

Aug 13, 2026

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 12, 2026

Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat

Aug 12, 2026

Aug 11, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Aug 11, 2026

Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade

Aug 11, 2026

Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times

Aug 11, 2026

KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView

Aug 11, 2026

Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan

Aug 11, 2026

Aug 09, 2026

Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 09, 2026

Aug 07, 2026

Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView

Aug 07, 2026